Unipolar Depression – Current Treatment – Special Topics (US): Fast-Acting Antidepressants: Ketamine And Ketamine-Like Products
Market Outlook
Despite the broad availability of antidepressants and atypical antipsychotics approved to treat major depressive disorder (MDD), approximately one-third of these patients are treatment resistant (i.e., MDD patients who do not respond to two adequate course of antidepressants). The prevalence of treatment-resistant depression (TRD) has contributed to psychiatrists’ off-label use of ketamine (an anesthetic that can induce depressive symptom relief in TRD patients within hours of treatment administration) and to development of treatments with novel mechanisms of action that can address this cohort of patients’ depressive symptoms and provide rapid relief. Understanding psychiatrists’ clinical use of ketamine and expected use of late-phase emerging fast-acting antidepressants will help drug developers determine which clinical attributes their agents should target and future positioning in this market.
Questions Answered
When and why do psychiatrists introduce the different formulations of ketamine (e.g., intranasal, intravenous) into their patients’ treatment paradigm? What are the obstacles to use of each formulation?
How long are patients typically treated with select formulations of ketamine? What percentage of patients discontinue ketamine treatment and why?
Is ketamine typically prescribed in combination with other therapies? If so, what pharmacological and/or nonpharmacological treatments are prescribed in combination with ketamine?
To which of their MDD patients do psychiatrists anticipate prescribing the emerging therapies esketamine (Janssen) and rapastinel (Allergan)?
Additional Tools Available
Primary market research survey available to download.
Markets covered: United States
Primary research: Survey of 100 psychiatrists in United States
Unipolar Depression - Current Treatment - Special Topics (US): Fast-Acting Antidepressants: Ketamine And Ketamine-Like Products
Special Topics - Unipolar Depression (Fast-Acting Antidepressants - Ketamine and Ketamine-Like Products) US
Executive Summary
Background
Key Findings
Percentage of Patients Receiving Ketamine by Subtype
Factors Constraining Psychiatrists' Use of Ketamine for the Treatment of MDD
Lisa Cloonan
Lisa Cloonan is a business insights analyst on the CNS/Ophthalmology Disorders team at DRG, part of Clarivate. In this role, she analyzes the commercial opportunities for pharmacological therapies in the psychiatry space. Prior to joining DRG, Ms. Cloonan spent six years researching clinical stroke at Massachusetts General Hospital. While there, she developed expertise in neuroimaging analysis, as well as authored and coauthored articles on the influence of white matter hyperintensity burden on stroke risk and recovery. She holds a bachelor of arts degree from Connecticut College, where her course work focused on behavioral neuroscience.
